Navigation Links
IU Confidential Publishes Biotech Investment Report
Date:7/28/2011

NEW YORK, July 28, 2011 /PRNewswire/ -- Investor Uprising Confidential, the premium investment research service of Investor Uprising, has published its "Best of Biotech: Innovation in Life Sciences" report today. The 16-page report covers the hottest trends in biotech investing, tells investors how to get involved, and gives an overview of more than 16 companies including a model portfolio of 10 top stock picks.

(Logo: http://photos.prnewswire.com/prnh/20110728/NY41230LOGO)

Biotech stocks have been among the best performers of the last five years, according to Investor Uprising Confidential's research, and many of these gains are driven by scientific innovation in the biopharmaceuticals and diagnostics markets. This innovation cycle is likely to continue for some time, making biotech an attractive place to invest.

"Many investors remain unaware of the strength in biotech and are mystified about how to invest in the market," says Investor Uprising Confidential's Editor and Publisher, R. Scott Raynovich. "Consequently, they have missed out. We put together a report that covers all the trends and explains many different ways to get involved, including ETFs, mutual funds, and individual stocks."

The report includes summaries of 17 leading biotechnology companies, three mutual funds, and the leading biotech Exchange Traded Funds (ETFs). Among the companies included in the report are Amgen Inc. (Nasdaq: AMGN), Biogen Idec  (Nasdaq: BIIB), Celgene Inc. (Nasdaq: CELG), Gilead Sciences Inc. (Nasdaq: GILD), Vertex
'/>"/>

SOURCE Investor Uprising
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
2. New Medical Supply Website Provides Confidentiality, Discounts for Consumers
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. GSK Publishes Payments for Research, Consulting and Advising by U.S. Healthcare Professionals
5. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
6. Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011
7. Radiology Journal Publishes Data That PEM Scanners May Reduce Unnecessary Breast Biopsies and Offer an Alternative for Women Who Cannot Tolerate MRI
8. Cellectis Publishes Its Financial Statement for the First Half of 2010
9. Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
10. Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool
11. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... /CNW/ - Alliance Principle Ingredients/Neutrical Solutions Inc., in consultation ... Galenic Health Ginger in Bentonite (NPN 80053535) due ... children. The product currently contains levels of lead ... limits for adult dosing. Ginger in ... disturbances. Alliance Principle Ingredients / Neutrical Solutions Inc. ...
(Date:5/29/2015)... BEDFORD, Mass. , May 29, 2015  Hologic, ... Company has entered into a new, five-year secured credit ... and a $1 billion revolving credit facility. ... initially, and used these proceeds and the Term Loan ... loans, which had an aggregate principal amount outstanding of ...
(Date:5/29/2015)... Ill. , May 29, 2015  Today, ... MasterControl, a leading global provider of electronic quality ... a collaborative agreement which will leverage the strengths ... with both quality system implementation and comprehensive advice ... Adding MasterControl,s EQMS capabilities to UL,s strength ...
Breaking Medicine Technology:Hologic Enters into Five-Year Secured Credit Agreement 2Hologic Enters into Five-Year Secured Credit Agreement 3UL and MasterControl collaborate to provide medical manufacturers full service QMS and Regulatory Submissions support 2UL and MasterControl collaborate to provide medical manufacturers full service QMS and Regulatory Submissions support 3
... VIRGINIA BEACH, Va., July 8, 2011 The Amerigroup ... check to the Rx Partnership to benefit the Rockbridge ... is an organization that works to provide uninsured Virginians ... as a broker to access and distribute free bulk ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III ... patients taking Afinitor® (everolimus) tablets* experienced a 50% ... subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors ... the largest prospective clinical trial to date in ...
Cached Medicine Technology:Amerigroup Foundation Presents Grant to Rx Partnership 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 3Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 4Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 5Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 6Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 7Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 8Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 9Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 10Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 11Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 12Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 13
(Date:5/29/2015)... Montclair, NJ (PRWEB) May 30, 2015 ... and ever changing local and federal regulations, we ... needs of their patients who are suffering from ... regulations,” says Srinivas Nalamachu, MD, professor of rehabilitation ... Research Institute in Overland Park, Kansas. , A ...
(Date:5/29/2015)... Washington, PA (PRWEB) May 29, 2015 ... ” quiz-based learning in 14 medical specialties, now offers ... includes a wide spectrum of rheumatology disorders ranging from ... Alfred Saint Jacques, editorial director of MDLinx, and Caroline ... excited about the impact it will have on the ...
(Date:5/29/2015)... May 29, 2015 The science of ... last decade. New and more efficient methods of FUE hair ... balding patients. One of the most cutting edge hair transplant ... Restoration is the technique of extracting hair from the beard ... are performed to correct male pattern baldness. Beard ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and her son, ... God does no wrong. , It’s fitting, then, that her ... titled “God Does No Wrong.” It focuses on what happens ... , “My story has a positive message about channeling ... productive, something healing,” Howse said. , “God Does No Wrong” ...
(Date:5/29/2015)... New York, New York (PRWEB) May 29, 2015 ... and distributor of patented products, announces that it has ... Chat Room, a technology patent that aims to let ... various industry experts in real time. , "This is ... Expert Chat Room " said Scott J. Cooper, CEO ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Turning grief from a child’s passing into virtue 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5
... American College of Physicians (ACP) and the Infectious Diseases ... on the importance of adult vaccination against an increasing ... by 17 other medical societies representing a range of ... Control and Prevention, 95 percent of vaccine-preventable diseases occur ...
... 19 NuVasive, Inc. (Nasdaq: NUVA ), a ... surgical treatments for the spine, announced today that Alex Lukianov, ... the 20th Annual Piper Jaffray Health Care Conference at The ... 10:30 a.m. ET. , , ...
... Microsoft Corp. today,announced that Blue Cross ... private health carrier, has saved nearly a ... system. Implemented to overhaul,incentive compensation and agent ... VUE Compensation Management, a Microsoft .NET,Framework-based application, ...
... of URAC,s Comprehensive Wellness Accreditation standards , ... announced today that its Board of Directors has approved ... These innovative standards reinforce and support the commitment ... health and productivity of America,s workforce. Comprehensive Wellness ...
... and,president of Ellie,s Meditative Movements, announces the arrival of ... new direction and fulfillment. Meditative,Movements(TM) is the companion ... , Ms. Peterson ... challenge,of raising three children alone, then explains the victory ...
... Erosion and a Dearth of Promising Emerging Therapies Will ... Report from Decision Resources , , ... Decision Resources, one of the world,s leading research ... that, owing to their improvements in safety and efficacy, ...
Cached Medicine News:Health News:Medical societies: Adults need vaccines 2Health News:NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference 2Health News:NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference 3Health News:Blue Cross and Blue Shield of Vermont Saves Nearly a Half-Million Dollars with a Microsoft Partner Compensation Management Solution 2Health News:Blue Cross and Blue Shield of Vermont Saves Nearly a Half-Million Dollars with a Microsoft Partner Compensation Management Solution 3Health News:Blue Cross and Blue Shield of Vermont Saves Nearly a Half-Million Dollars with a Microsoft Partner Compensation Management Solution 4Health News:URAC Announces Accreditation Standards for Comprehensive Wellness Programs 2Health News:URAC Announces Accreditation Standards for Comprehensive Wellness Programs 3Health News:URAC Announces Accreditation Standards for Comprehensive Wellness Programs 4Health News:Meditative Movements(TM), State-of-the-Art Fitness Guidebook, Now Available 2Health News:Uptake of Next-Generation Antifungals Has Intensified Competition in the Severe Fungal Infections Drug Market 2
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
... Antibody (IgG) Test is a semiquantitative enzyme ... significant IgG antibodies to M. pneumoniae between ... test should not be used for specimens ... (IgM) Test and is not intended for ...
... Test is a qualitative enzyme immunoassay ... Epstein-Barr virus capsid antigen (EBV-VCA), Epstein-Barr ... and Toxoplasma. When used in conjunction ... aid in the serodiagnosis of infectious ...
... Test is an enzyme immunoassay ... the presence of antibodies to ... and herpes simplex virus in ... to indicate previous or current ...
Medicine Products: